Science42:DORA at a glance
Science42:DORA is an AI data & analytics tool. An AI platform for drug discovery that identifies novel targets, predicts drug response, and optimizes clinical trials using multi-omics data.
- Best for:
- Company: Pharma.AI (subsidiary of Insilico Medicine)
- Pricing:
- Contact for pricing — Enterprise-level pricing for pharmaceutical and biotech companies; not publicly listed
- Standout feature:
- Novel target identification and prioritization
- Main limitation:
- Extremely niche and complex, requiring significant domain expertise in biology and pharmacology
About Science42:DORA
Science42:DORA is an AI-powered platform developed by Pharma.AI (an Insilico Medicine company) designed to accelerate drug discovery and development. DORA, which stands for 'Drug Outcome and Response AI,' focuses on analyzing multi-omics data, biomedical literature, and clinical trial information to identify novel drug targets, predict drug efficacy, and optimize clinical trial design. It leverages generative AI and biological pathway analysis to propose new therapeutic hypotheses and de-risk R&D decisions. The tool is best for pharmaceutical companies, biotech research teams, and academic institutions engaged in early-stage drug discovery who need to prioritize targets and understand complex disease biology. Compared to general-purpose data science platforms or older bioinformatics suites, DORA is specifically tailored for the drug discovery pipeline, integrating proprietary biological knowledge graphs. Its key differentiator is its connection to Insilico Medicine's end-to-end AI-driven drug discovery ecosystem, which includes target identification (PandaOmics) and generative chemistry (Chemistry42), offering a more integrated solution than standalone target prediction tools.
